Publication of Prospectus
Hemogenyx Pharmaceuticals plc has published a Prospectus announcing the admission of 116,982 new ordinary shares from convertible loan note conversions and 439,629 new ordinary shares from warrant exercises to the Official List and the Main Market of the London Stock Exchange. These new ordinary shares are expected to be admitted and commence unconditional dealings on 24 November 2025.
Select text to share a quote on X · sign in to keep highlights & notes in your HEMO notes
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN OR INTO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION
Hemogenyx Pharmaceuticals plc
("Hemogenyx Pharmaceuticals" or the "Company")
Publication of Prospectus
The Company is pleased to announce today the publication of a Prospectus in relation to the admission of 116,982 new ordinary shares of 0.01 pence each to be issued upon conversion of convertible loan notes issued by the Company on 31 August 2025 (the "Convertible Loan Notes Shares") and 439,629 new ordinary shares of 0.01 pence each to be issued following the exercise of certain of the warrants issued by the Company during 2025 (the "Warrant Shares") (together the "New Ordinary Shares") to listing in the equity shares (transition) category of the Official List of the FCA and to trading on the Main Market of the London Stock Exchange (together, "Admission").
It is expected that Admission will become effective, and unconditional dealings in the New Ordinary Shares will commence on 24 November 2025.
An electronic copy of the Prospectus will also be submitted to the National Storage Mechanism and should be available shortly for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.